Table 1.
Baseline characteristics from the training and validation datasets
| Training | Validation | P-value | |
|---|---|---|---|
| Age, years (range) | 60.4 (36–88) | 60.4 (31–84) | 0.331 |
| Sex, n (%) | 0.045 | ||
| Male | 164 (75.2%) | 144 (66.1%) | |
| Female | 54 (24.8%) | 74 (33.9%) | |
| Smoking history, n (%) | 0.101 | ||
| Never | 112 (51.4%) | 130 (59.6%) | |
| Former/current | 106 (48.6%) | 88 (40.4%) | |
| Metastatic sites, n (%) | 0.233 | ||
| 1–2 | 208 (95.4%) | 201 (92.2%) | |
| 3 | 10 (4.6%) | 17 (7.8% | |
| Classification, n (%) | 0.690 | ||
| Synchronous | 137 (62.8%) | 142 (65.1%) | |
| Metachronous | 81 (37.2%) | 76 (34.9%) | |
| Pathology, n (%) | 0.616 | ||
| Adenocarcinoma | 164 (75.2%) | 171 (78.4%) | |
| Non-adenocarcinoma | 47 (21.6%) | 45 (20.6%) | |
| Unknown | 7 (3.2%) | 2 (1.0%) | |
| EGFR status, n (%) | 0.911 | ||
| Negative | 110 (50.5%) | 107 (49.1%) | |
| Positive | 77 (35.3%) | 82 (37.6%) | |
| Unknown | 31 (14.2%) | 29 (13.3%) | |
| T stage, n (%) | 0.851 | ||
| T0–2 | 149 (68.3%) | 155 (71.1%) | |
| T3–4 | 67 (30.7%) | 61 (27.9%) | |
| N stage, n (%) | 0.282 | ||
| N0 | 49 (22.5%) | 63 (28.9%) | |
| N+ | 169 (77.5%) | 155 (71.1%) | |
| LCT | 0.968 | ||
| Surgery | 17 (7.8%) | 15 (6.9%) | |
| Radiotherapy | 79 (36.2%) | 80 (36.7%) | |
| Both | 4 (1.8%) | 3 (1.4%) | |
| Neither | 118 (54.2%) | 120 (55.0%) | |
| Total | 218 | 218 |
EGFR epidermal growth factor receptor; LCT local consolidative therapy